Your browser is no longer supported. Please, upgrade your browser.
Cellectar Biosciences, Inc.
Index- P/E- EPS (ttm)-1.19 Insider Own0.40% Shs Outstand26.33M Perf Week-15.11%
Market Cap91.91M Forward P/E- EPS next Y-0.52 Insider Trans62.56% Shs Float19.66M Perf Month7.30%
Income-14.90M PEG- EPS next Q-0.15 Inst Own48.10% Short Float11.74% Perf Quarter57.85%
Sales- P/S- EPS this Y64.90% Inst Trans159.63% Short Ratio0.76 Perf Half Y59.17%
Book/sh0.57 P/B3.35 EPS next Y37.30% ROA-90.80% Target Price- Perf Year-9.48%
Cash/sh0.39 P/C4.89 EPS next 5Y- ROE-129.40% 52W Range1.01 - 2.98 Perf YTD-8.17%
Dividend- P/FCF- EPS past 5Y59.80% ROI- 52W High-33.22% Beta1.59
Dividend %- Quick Ratio5.00 Sales past 5Y- Gross Margin- 52W Low97.02% ATR0.23
Employees8 Current Ratio5.00 Sales Q/Q- Oper. Margin- RSI (14)44.44 Volatility10.69% 11.08%
OptionableNo Debt/Eq0.00 EPS Q/Q64.30% Profit Margin- Rel Volume0.30 Prev Close1.91
ShortableYes LT Debt/Eq0.01 EarningsMar 02 BMO Payout- Avg Volume3.03M Price1.99
Recom1.70 SMA20-10.36% SMA50-6.23% SMA20029.78% Volume372,939 Change4.18%
Jul-01-20Initiated Oppenheimer Outperform
Jan-21-20Resumed ROTH Capital Buy $10
Sep-13-19Initiated ROTH Capital Buy
Dec-21-16Initiated Ladenburg Thalmann Buy $2.70
Mar-02-21 08:30AM  
Feb-10-21 08:30AM  
Jan-27-21 08:30AM  
Jan-12-21 09:09AM  
Dec-28-20 04:05PM  
Dec-23-20 08:39AM  
Dec-22-20 05:28PM  
Dec-06-20 02:12AM  
Dec-01-20 11:35AM  
Nov-27-20 04:13PM  
Nov-09-20 08:44AM  
Nov-05-20 09:00AM  
Sep-10-20 08:00AM  
Sep-09-20 08:00AM  
Aug-17-20 10:01AM  
Aug-10-20 08:00AM  
Aug-04-20 08:00AM  
Jul-29-20 03:31PM  
Jul-21-20 08:00AM  
Jul-01-20 08:00AM  
Jun-11-20 08:30AM  
Jun-09-20 06:33AM  
Jun-05-20 04:01PM  
Jun-03-20 09:00AM  
Jun-01-20 08:00AM  
May-28-20 10:10AM  
May-27-20 10:56AM  
May-26-20 07:45AM  
May-14-20 08:00AM  
May-07-20 08:15AM  
Apr-16-20 07:04AM  
Mar-09-20 08:00AM  
Feb-19-20 08:00AM  
Jan-17-20 06:41AM  
Jan-09-20 08:00AM  
Jan-07-20 08:00AM  
Jan-06-20 08:00AM  
Dec-19-19 08:00AM  
Dec-16-19 08:00AM  
Dec-13-19 08:31AM  
Dec-09-19 08:30AM  
Dec-02-19 08:30AM  
Nov-12-19 08:00AM  
Oct-30-19 08:00AM  
Oct-19-19 09:44AM  
Oct-17-19 08:00AM  
Oct-15-19 08:00AM  
Oct-08-19 08:00AM  
Sep-30-19 08:30AM  
Sep-24-19 08:00AM  
Sep-19-19 08:30AM  
Sep-16-19 08:30AM  
Sep-10-19 08:00AM  
Sep-04-19 08:00AM  
Aug-20-19 12:37PM  
Aug-15-19 08:30AM  
Aug-14-19 08:30AM  
Aug-12-19 08:00AM  
Jul-09-19 08:30AM  
May-21-19 08:30AM  
May-20-19 04:10PM  
May-18-19 07:15AM  
May-16-19 08:52AM  
May-15-19 08:30AM  
May-13-19 08:00AM  
May-06-19 08:00AM  
May-02-19 02:18PM  
Apr-29-19 10:20AM  
Apr-10-19 01:40PM  
Mar-19-19 08:30AM  
Feb-26-19 08:30AM  
Feb-25-19 08:30AM  
Feb-05-19 08:30AM  
Jan-23-19 08:00AM  
Jan-22-19 02:15PM  
Jan-07-19 08:30AM  
Jan-03-19 08:30AM  
Dec-11-18 08:30AM  
Dec-04-18 08:30AM  
Nov-21-18 02:53PM  
Nov-13-18 08:30AM  
Nov-12-18 08:30AM  
Oct-02-18 08:00AM  
Sep-27-18 08:30AM  
Sep-25-18 08:30AM  
Sep-24-18 08:00AM  
Sep-17-18 08:43AM  
Aug-29-18 08:30AM  
Aug-20-18 08:30AM  
Aug-13-18 09:25AM  
Aug-10-18 08:00AM  
Aug-01-18 08:30AM  
Jul-31-18 04:05PM  
Jul-27-18 08:30AM  
Jul-18-18 08:20AM  
Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is targeted to treat solid tumors. It has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; Avicenna Oncology GMBH to develop CLR 2000 Series; Onconova Therapeutics, Inc. to develop CLR 2100 and 2200 Series; and Orano Med to develop novel PDCs. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Longcor JarrodChief Business OfficerDec 28Buy1.3529,63040,000102,148Dec 28 04:31 PM
CARUSO JAMES VPresident and CEODec 28Buy1.3537,03750,00081,301Dec 28 04:31 PM
Elefant DovChief Financial OfficerDec 28Buy1.357,4079,99911,755Dec 28 04:30 PM
Elefant DovChief Financial OfficerJun 05Buy1.154,3484,9784,348Jun 08 04:08 PM
Longcor JarrodChief Business OfficerJun 05Buy1.1565,21874,67572,518Jun 08 04:08 PM
CARUSO JAMES VPresident and CEOJun 05Buy1.1521,74024,89244,264Jun 08 04:07 PM
HILL STEPHEN ADirectorJun 04Buy1.0818,00019,43818,000Jun 08 04:12 PM